Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

POPLAR study of imsidolimab in palmoplantar pustulosis does not meet primary endpoint

March 9, 2021

Topline data from BRAVE-AA2 phase III study of baricitinib in severe alopecia areata

March 4, 2021

BiomX begins phase II study of BX-001 for acne

March 3, 2021

VYNE advances development of FMX-114 combination topical gel for AD

March 3, 2021

Fighting Staphylococcus with Staphylococcus

March 3, 2021

Kymera begins dosing in first-in-human study of KT-474 for atopic dermatitis or HS

March 2, 2021

Hoth advances site recruitment for first-in-human study of BioLexa for atopic dermatitis

March 2, 2021

Aslan reports promising clinical data on ASLAN-004 in atopic dermatitis

March 1, 2021

Celldex plans clinical study of CDX-0159 in prurigo nodularis

Feb. 23, 2021

Phase II study of Thykamine in atopic dermatitis meets its primary endpoint

Feb. 19, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...